Research ExplorerPublicationsLong-term effects of intravenous iloprost in patients with i...

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

Standard

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. / Knudsen, Lars; Schurawlew, Alexander; Nickel, Nils; Tiede, Henning; Ghofrani, Hossein A; Wilkens, Heinrike; Ewert, Ralf; Halank, Michael; Klose, Hans; Bäzner, Carlos; Behr, Jürgen; Hoeper, Marius M.

In: BMC PULM MED, Vol. 11, 2011, p. 56.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Knudsen, L, Schurawlew, A, Nickel, N, Tiede, H, Ghofrani, HA, Wilkens, H, Ewert, R, Halank, M, Klose, H, Bäzner, C, Behr, J & Hoeper, MM 2011, 'Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.', BMC PULM MED, vol. 11, pp. 56. https://doi.org/10.1186/1471-2466-11-56

APA

Knudsen, L., Schurawlew, A., Nickel, N., Tiede, H., Ghofrani, H. A., Wilkens, H., Ewert, R., Halank, M., Klose, H., Bäzner, C., Behr, J., & Hoeper, M. M. (2011). Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC PULM MED, 11, 56. https://doi.org/10.1186/1471-2466-11-56

Vancouver

Knudsen L, Schurawlew A, Nickel N, Tiede H, Ghofrani HA, Wilkens H et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC PULM MED. 2011;11:56. https://doi.org/10.1186/1471-2466-11-56

Bibtex

@article{0dcfcf0f984242c8912922ddb52130aa,
title = "Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.",
abstract = "The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail, current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.",
keywords = "Adult, Humans, Male, Female, Middle Aged, Treatment Outcome, Survival Analysis, Retrospective Studies, Administration, Oral, Drug Therapy, Combination, Injections, Intravenous, Hypertension, Pulmonary/*drug therapy, Iloprost/administration & dosage/*therapeutic use, Phosphodiesterase Inhibitors/therapeutic use, Receptors, Endothelin/antagonists & inhibitors, Vasodilator Agents/administration & dosage/*therapeutic use, Adult, Humans, Male, Female, Middle Aged, Treatment Outcome, Survival Analysis, Retrospective Studies, Administration, Oral, Drug Therapy, Combination, Injections, Intravenous, Hypertension, Pulmonary/*drug therapy, Iloprost/administration & dosage/*therapeutic use, Phosphodiesterase Inhibitors/therapeutic use, Receptors, Endothelin/antagonists & inhibitors, Vasodilator Agents/administration & dosage/*therapeutic use",
author = "Lars Knudsen and Alexander Schurawlew and Nils Nickel and Henning Tiede and Ghofrani, {Hossein A} and Heinrike Wilkens and Ralf Ewert and Michael Halank and Hans Klose and Carlos B{\"a}zner and J{\"u}rgen Behr and Hoeper, {Marius M}",
year = "2011",
doi = "10.1186/1471-2466-11-56",
language = "English",
volume = "11",
pages = "56",
journal = "BMC PULM MED",
issn = "1471-2466",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

AU - Knudsen, Lars

AU - Schurawlew, Alexander

AU - Nickel, Nils

AU - Tiede, Henning

AU - Ghofrani, Hossein A

AU - Wilkens, Heinrike

AU - Ewert, Ralf

AU - Halank, Michael

AU - Klose, Hans

AU - Bäzner, Carlos

AU - Behr, Jürgen

AU - Hoeper, Marius M

PY - 2011

Y1 - 2011

N2 - The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail, current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.

AB - The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail, current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Survival Analysis

KW - Retrospective Studies

KW - Administration, Oral

KW - Drug Therapy, Combination

KW - Injections, Intravenous

KW - Hypertension, Pulmonary/drug therapy

KW - Iloprost/administration & dosage/therapeutic use

KW - Phosphodiesterase Inhibitors/therapeutic use

KW - Receptors, Endothelin/antagonists & inhibitors

KW - Vasodilator Agents/administration & dosage/therapeutic use

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Survival Analysis

KW - Retrospective Studies

KW - Administration, Oral

KW - Drug Therapy, Combination

KW - Injections, Intravenous

KW - Hypertension, Pulmonary/drug therapy

KW - Iloprost/administration & dosage/therapeutic use

KW - Phosphodiesterase Inhibitors/therapeutic use

KW - Receptors, Endothelin/antagonists & inhibitors

KW - Vasodilator Agents/administration & dosage/therapeutic use

U2 - 10.1186/1471-2466-11-56

DO - 10.1186/1471-2466-11-56

M3 - SCORING: Journal article

VL - 11

SP - 56

JO - BMC PULM MED

JF - BMC PULM MED

SN - 1471-2466

ER -